Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we look at how a China biotech crackdown could benefit Europe, what a rival drug failure might mean for Alnylam, the algorithm behind the Moderna-Merck cancer vaccine, and a landmark approval in pancreatic cancer.
RIP, Tim Curry. I shall mourn how humbly you buttle.
The need-to-know this morning
Moderna is raising $2 billion in convertible debt. The new financing comes one week after the Phase 3 success of its personalized cancer vaccine.
